The platelet-function analyzer (PFA-100®) for evaluating primary hemostasis

Hematology

Volumn 10, Issue 3, 2005, Pages 177-181

  Franchini, Massimo ^a,b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b OSPEDALE POLICLINICO   (Italy)

Author keywords

Hemostasis; PFA 100; Platelet aggregation; Platelet function analyzer

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DESMOPRESSIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDINE DERIVATIVE; THIENOPYRIDINE; UNCLASSIFIED DRUG;

ANALYZER; BERNARD SOULIER DISEASE; BLEEDING TIME; CLINICAL PRACTICE; GLANZMANN DISEASE; HEMOPHILIA; HEMOSTASIS; HUMAN; IN VIVO STUDY; MEDICAL LITERATURE; MEDLINE; OCULAR ALBINISM; PRIORITY JOURNAL; REVIEW; STORAGE DISEASE; SURGICAL TECHNIQUE; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE; BLOOD; BLOOD CLOTTING PARAMETERS; DIAGNOSIS, MEASUREMENT AND ANALYSIS; INSTRUMENTATION; METHODOLOGY; SENSITIVITY AND SPECIFICITY; THROMBOCYTE DISORDER;

BLOOD PLATELET DISORDERS; HEMOSTASIS; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PLATELET FUNCTION TESTS; SENSITIVITY AND SPECIFICITY; VON WILLEBRAND DISEASE;

EID: 25144504902     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330400026097     Document Type: Review

References (54)

1. Favaloro EJ. Clinical application of the PFA-100®. Curr Opin Hematol 2002;9:407-415.
2. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16:1-20.
3. Harrison P. Advances in platelet function analysis. Br J Haematol 2000;111:733-744.
4. Kratzer MAA, Born GVR. Simulation of primary haemostasis in vitro. Haemostasis 1985;5:537-562.
5. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer - PFA-100®. Semin Thromb Hemost 1995; 21(Suppl. 2):106-112.
6. Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100® system. Semin Thromb Hemost 1995;21(Suppl. 2):113-120.
7. Lippi G, Franchini M. Laboratory screening for abnormalities of primary hemostasis: what's next? Clin Chem 2001;47:2071.
8. Rand ML, Leung R, Packhman MA. Platelet function assays. Transfus Apheresis Sci 2003;28:307-317.
9. Favaloro EJ. Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy: A review analytical variables, benefits and limitations. Haemophilia 2001;7:170-179.
10. Jilma B. Platelet function analyzer (PFA-100)®: A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152-163.
11. Lippi G, Franchini M, Gandini G, Manzato F. Establishment of reference values on the novel PFA-100® system. Clin Chem 1999;45:A62.
12. Bock M, De Haan J, Beck KH, et al. Standardization of the PFA-100® platelet function test in 105 mmol/L buffered citrate: Effect of gender, smoking, and oral contraceptives. Br J Haematol 1999;106:898-904.
13. Sestito A, Sciahbasi A, Landolfi R, Maseri A, Lanza GA, Andreotti F. A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100®): Reproducibility and effects of sex and age. Cardiologia 1999;44:661-665.
14. Rand ML, Carcao MD, Blanchette VS. Use of the PFA-100® in the assessment of primary, platelet-related hemostasis in a pediatric setting. Semin Thromb Hemost 1998;24:523-529.
15. Carcao MD, Blanchette VS, Dean JA, et al. The platelet function analyzer (PFA-100®): A novel in vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998;101:70-73.
16. Lippi G, Manzato F, Franchini M, Brocco G, Florenziani G, Guidi G. Establishment of reference values for the PFA-100® platelet function analyzer in pediatrics. Clin Exp Med 2001;1:69.
17. Heilmann EJ, Kundu SK, Sio R, Garcia C, Gomez R, Christie DJ. Comparison of four commercial citrate blood collection systems for platelet function analysis of the PFA-100® system. Thromb. Res. 1997;87:159-164.
18. Reiter RA, Mayr F, Blazicek H, et al. Desmopressin and platelets antagonize the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102:4594-4599.
19. von Pape KW, Aland E, Bohner J. Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood samples. Thromb Res 2000; 98:295-299.
20. Jilma-Stohlawetz P, Hergovich N, Homoncik M, et al. Impaired platelet function among platelet donors. Thromb Haemost 2001;86:880-886.
21. Lippi G, Franchini M, Brocco F, Manzato F. Influence of the ABO blood type on the platelet function analyzer PFA-100®. Thromb Haemost 2001;85:369-370.
22. Escolar G, Cases A, Viñas M, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100®): Influence of hematocrit elevation. Haematologica 1999;84:614-619.
23. Harrison P, Robinson MSC, Mackie IJ, et al. Performance of the platelet function analyser PFA-100® in testing abnormalities of primary hemostasis. Blood Coagul Fibrinol 1999;10:25-31.
24. Kerenyi A, Schlammadinger A, Ajzner E, et al. Comparison of the PFA-100® closure time and template bleeding time of patients with inherited disorders causing defective platelet function. Thromb Res 1999;96:487-492.
25. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases. Blood 1998;91:1325-1331.
26. Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti ML. Evaluation of platelet function with the PFA-100® system in patients with congenital defects of platelet secretion. Thromb Res 1999;96:213-217.
27. Borzini P, Lazzaro A, Mazzucco L. Evaluation of hemostatic function of stored platelet concentrates using the platelet function analyzer (PFA-100)®. Haematologica 1999; 84:1104-1109.
28. Harrison P, Segal H, Furtado C, Verjee S, Sukhu K, Murphy MF. High incidence of defective high-shear platelet function among platelet donors. Transfusion 2004;44:764-770.
29. Paglieroni TG, Janatpour K, Gosselin R, et al. Platelet function abnormalities in qualified whole-blood donors: Effects of medication and recent food intake. Vox Sang 2004;86:48-53.
30. Veyradier A, Fressinaud E, Boyer-Neumann C, Trossaert M, Meyer D. von Willebrand factor ristocetin cofactor activity correlates with platelet function in a high shear stress system. Thromb Haemost 2000;84:727-728.
31. Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, Le Boterff C, Meyer D. Therapeutic monitoring of von Wilelbrand disease: Interest and limits of a platelet function analyser at high shear stress. Br J Haematol 1999; 106:777-783.
32. Cattaneo M, Federici AB, Lecchi A, et al. Evaluation of the PFA-100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999;82:35-39.
33. Favaloro EJ. Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder. Best Pract Res Clin Haematol 2001;14:299-319.
34. Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand disease. Blood Rev 1999;13:185-204.
35. Franchini M, Gandini G, Manzato F, Lippi G. Evaluation of the PFA-100® system for monitoring desmopressin therapy in patients with type 1 von Willebrand's disease. Haematologica 2002;87:670.
36. de Meijer A, Vollaard H, de Metz M, Verbruggen B, Thomas C, Novakova I. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers. Clin Pharmacol Ther 1999; 66:425-430.
37. Homoncik M, Malec M, Marsik C, et al. Rofecoxib exerts no effect on platelet plug formation in healthy volunteers. Clin Exp Rheumatol 2003;21:229-231.
38. Ortel TL, James AH, Thames EH, Moore KD, Greenberg CS. Assessment of primary hemostasis by PFA-100® analysis in a tertiary care center. Thromb Haemost 2000;84:93-97.
39. Marshall PW, Williams AJ, Dixon RM, et al. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100®, in healthy volunteers. Br J Clin Pharmacol 1997;44:151-155.
40. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100®. Thromb Haemost 2000;83:316-321.
41. Derhaschnig U, Pachinger C, Jilma B. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: A randomized, placebo-controlled, clinical trial. Am Heart J 2004;147:E17.
42. Hezard N, Metz D, Nazeyrollas P, et al. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thromb Haemost 2000;83:540-544.
43. Hezard N, Metz D, Nazeyrollas P, Droulle C, Potron G, Nguyen P. PFA-100 and flow cytometry: Can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? Thromb Res 2002;108:43-47.
44. Madan M, Berkowitz SD, Christie DJ, et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 2001;141:226-233.
45. Madan M, Berkowitz SD, Christie DJ, Smit AC, Sigmon KN, Tcheng JE. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am Heart J 2002;144:151-158.
46. Renda G, Rocca B, Crocchiolo R, Cristofaro RD, Landolfi R. Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban. Thromb Haemost 2003;89:348-354.
47. Watala C, Golanski J, Rozalski M, et al. Is platelet aggregation a more important contributor than platelet adhesion to the overall platelet-related primary haemostasis measured by PFA-100? Thromb Res 2003;109:299-306.
48. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: A case-crossover study. Stroke 2003;34:849-854.
49. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003;145:239-247.
50. Van der Planken MG, Claeys MJ, Vertessen FJ, et al. Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb Res 2003;111:159-164.
51. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 2002;13:493-497.
52. Francis JL, Francis D, Larson L, Helms E, Garcia M. Can the platelet function analyser (PFA-100®) test substitute for the template bleeding time in routine clinical practice? Platelets 1999;10:132-136.
53. Schulz-Stubner S, Zielske D, Rossaint R. Comparison between nasal and intravenous desmopressin for the treatment of aminosalicylic acid-induced platelet dysfunction. Eur J Anaesthesiol 2002;19:647-651.
54. Cariappa R, White TR, Parvin CA, Luchtman-Jones L. Comparison of the PFA-100® and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol 2003;25:474-479.